Lifeline Scientific, Inc Additional Listing (0585V)
23 10월 2014 - 2:24AM
UK Regulatory
TIDMLSI TIDMLSI TIDMLSIC
RNS Number : 0585V
Lifeline Scientific, Inc
22 October 2014
Lifeline Scientific, Inc. ("Lifeline" or "the Company")
Additional Listing
Lifeline Scientific, the medical technology company focused on
the development of innovative products that improve transplant
outcomes and lower the overall costs of transplantation, announces
the issue of 17,714 unrestricted shares under ISIN number
US53223V1017 following the exercise of Options by an employee and
former employee under the rules of the Company's 2007 Stock Option
and Restricted Stock Plan.
Application has been made to the London Stock Exchange for
admission to AIM of 17,714 common shares of USD0.01 each. It is
expected that admission will become effective in the Ordinary
Shares on or around the 24 October 2014.
Subsequent to the admission above there will be 19,464,434
common shares in issue and each share has the right to one vote.
Therefore for the purposes of the FCA Disclosure and Transparency
Rules the total number of voting rights in the Company is
19,464,434.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine whether they are
required to notify the Company of their interests in, or change to
their interests in, Lifeline Scientific, Inc. under the FCA's
Disclosure and Transparency Rules.
Following this issue, 6,360,914 common shares remain registered
on the Regulation S register although no restrictions currently
apply to these shares they are held in certificated form only.
These common shares can be switched to the non-restricted line but
currently trade under ISIN number USU529641008.
The remaining 13,103,520 common shares have no restrictions, are
held in certificated or CREST format and trade under ISIN number
US53223V1017.
22 October 2014
For further information:
Lifeline Scientific, Inc. Tel: +1 847-294-0300
David Kravitz, CEO
Lisa Kieres, CFO
Panmure Gordon (UK) Limited Tel: +44 20 7886 2500
Freddy Crossley (Corporate Finance)
Maisie R Atkinson (Corporate Broking)
FTI Consulting Tel: +44 20 7831 3113
Simon Conway / John Dineen
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to provide improved kidney preservation, evaluation and
transport prior to transplantation. Today, it is widely recognised
as the world's leading machine preservation device for kidneys.
Employed by surgeons in over 135 leading transplant programmes in
23 countries worldwide, LifePorts have successfully preserved over
38,000 kidneys intended for clinical transplant. The product
provides a sealed, sterile, protected environment where a solution
is gently pumped through the kidney at cold temperatures to
minimise damage while the organ is outside the body. LifePort is
lightweight and portable, allowing organs to be perfused from the
time of recovery until transplant. It is designed to travel
unaccompanied by land or air, safely transporting the kidneys
across town or between countries. While the kidney is being
perfused, LifePort records data on temperature, flow rate, vascular
resistance and pressure every 10 seconds providing surgeons with
additional data prior to transplant. LifePort is the only system
with clinical outcomes data produced from an independent,
prospective, randomised, statistically powered, multi-centre
clinical trial. Study results have been widely published in
scientific journals, including the New England Journal of Medicine.
Data indicates that patients receiving LifePort preserved kidneys
experienced significant reduction in the incidence and duration of
delayed graft function and increased graft survival at 1-year and
3-years post transplant. LifePort has also been recognised for its
design and engineering. It has received prominent awards for design
excellence from the medical device industry, has been selected for
exhibition at the Smithsonian Cooper-Hewitt, National Design Museum
and is part of the permanent Collection of The Museum of Modern Art
(MoMA) in New York City.
About Lifeline Scientific, Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product is the FDA cleared, CE marked and
clinically validated LifePort Kidney Transporter. Devices for
preservation of the liver, pancreas, heart, and lung are in late
stage pre-clinical development.
see www.lifeline-scientific.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISZMMZGNZZGDZM
Lifeline Sci. S (LSE:LSI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Lifeline Sci. S (LSE:LSI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
